FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8092人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839927, encodeId=299a183992ef5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准吉利德的Trodelvy治疗三阴性乳腺癌, objectType=article, longId=209690, objectId=6a6f209690af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a6f209690af, replyNumber=0, likeNumber=74, createdTime=2021-11-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a6f209690af, moduleTitle=FDA批准吉利德的Trodelvy治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6f209690af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839857, encodeId=6fab183985ec8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=89, createdTime=2020-09-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839864, encodeId=575e183986466, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, objectType=article, longId=199783, objectId=eb8f199e83c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb8f199e83c9, replyNumber=0, likeNumber=84, createdTime=2020-08-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb8f199e83c9, moduleTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb8f199e83c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准非小细胞肺癌的辅助疗法，疾病复发率降低80％, objectType=article, longId=205616, objectId=59bb205616aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59bb205616aa, replyNumber=0, likeNumber=75, createdTime=2021-02-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59bb205616aa, moduleTitle=FDA批准非小细胞肺癌的辅助疗法，疾病复发率降低80％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59bb205616aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839901, encodeId=790b183990178, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, objectType=article, longId=204714, objectId=6286204e1417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6286204e1417, replyNumber=0, likeNumber=67, createdTime=2021-06-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6286204e1417, moduleTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6286204e1417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839931, encodeId=a4ab183993128, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2021年上半年盘点：FDA批准52款新药，6款生物制品, objectType=article, longId=213748, objectId=140d213e48a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=140d213e48a2, replyNumber=0, likeNumber=68, createdTime=2021-11-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=140d213e48a2, moduleTitle=2021年上半年盘点：FDA批准52款新药，6款生物制品, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=140d213e48a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839884, encodeId=e2941839884dd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准新的医疗器械漏洞评分工具CVSS, objectType=article, longId=202720, objectId=5b9a202e2069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b9a202e2069, replyNumber=0, likeNumber=72, createdTime=2021-07-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b9a202e2069, moduleTitle=FDA批准新的医疗器械漏洞评分工具CVSS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b9a202e2069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839867, encodeId=a25c183986eec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=罗氏诊断HIV-1/HIV-2定性检测试剂获FDA批准, objectType=article, longId=200168, objectId=c5422001680c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5422001680c, replyNumber=0, likeNumber=63, createdTime=2020-11-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5422001680c, moduleTitle=罗氏诊断HIV-1/HIV-2定性检测试剂获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5422001680c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839906, encodeId=f3461839906a0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌, objectType=article, longId=205839, objectId=b9a4205839dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a4205839dd, replyNumber=0, likeNumber=87, createdTime=2021-03-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a4205839dd, moduleTitle=美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a4205839dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839846, encodeId=1f66183984614, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=异源细胞疗法FCR001治疗重度硬皮病：IND已获FDA批准, objectType=article, longId=197299, objectId=56fc19e29943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56fc19e29943, replyNumber=0, likeNumber=62, createdTime=2020-08-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56fc19e29943, moduleTitle=异源细胞疗法FCR001治疗重度硬皮病：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56fc19e29943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839873, encodeId=72fa18398e343, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, objectType=article, longId=201255, objectId=b45e20125596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45e20125596, replyNumber=0, likeNumber=75, createdTime=2021-07-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45e20125596, moduleTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45e20125596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839892, encodeId=7caf1839892b0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准遗传性肥胖药物Imcivree, objectType=article, longId=203845, objectId=e49f203845de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e49f203845de, replyNumber=0, likeNumber=76, createdTime=2021-10-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e49f203845de, moduleTitle=FDA批准遗传性肥胖药物Imcivree, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e49f203845de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839897, encodeId=fe0f183989ed9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准转基因猪，推进医疗用途的异种移植, objectType=article, longId=204586, objectId=000020458657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=000020458657, replyNumber=0, likeNumber=60, createdTime=2021-03-28, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=000020458657, moduleTitle=美国FDA批准转基因猪，推进医疗用途的异种移植, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=000020458657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839888, encodeId=cefa183988855, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准替格瑞洛用于降低卒中风险, objectType=article, longId=203197, objectId=ad5920319eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad5920319eea, replyNumber=0, likeNumber=71, createdTime=2021-08-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad5920319eea, moduleTitle=FDA批准替格瑞洛用于降低卒中风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad5920319eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839919, encodeId=9b73183991984, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准第三款新冠疫苗紧急使用授权, objectType=article, longId=208098, objectId=ded120809874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ded120809874, replyNumber=0, likeNumber=59, createdTime=2021-12-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ded120809874, moduleTitle=FDA批准第三款新冠疫苗紧急使用授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ded120809874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839836, encodeId=240a1839836ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验, objectType=article, longId=196558, objectId=65c9196558ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65c9196558ff, replyNumber=0, likeNumber=98, createdTime=2021-03-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65c9196558ff, moduleTitle=FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65c9196558ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839878, encodeId=eaf418398e80e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, objectType=article, longId=202130, objectId=a6d020213007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d020213007, replyNumber=0, likeNumber=60, createdTime=2021-03-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d020213007, moduleTitle=Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6d020213007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839909, encodeId=1782183990954, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=艾滋病治疗革命：FDA批准长效HIV药物，每月仅需一次治疗, objectType=article, longId=206223, objectId=76c92062232b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76c92062232b, replyNumber=0, likeNumber=0, createdTime=2021-10-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76c92062232b, moduleTitle=艾滋病治疗革命：FDA批准长效HIV药物，每月仅需一次治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76c92062232b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839835, encodeId=d3f0183983581, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=PD-1单抗KEYTRUDA：首次获FDA批准治疗复发或转移性皮肤鳞状细胞癌, objectType=article, longId=196530, objectId=ecbe1965305c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecbe1965305c, replyNumber=0, likeNumber=73, createdTime=2021-02-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecbe1965305c, moduleTitle=PD-1单抗KEYTRUDA：首次获FDA批准治疗复发或转移性皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecbe1965305c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839886, encodeId=4bf91839886c7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=GE医疗的AI辅助心血管超声系统获得FDA批准，旨在缩短检查时间, objectType=article, longId=202933, objectId=9d812029338b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d812029338b, replyNumber=0, likeNumber=85, createdTime=2021-04-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d812029338b, moduleTitle=GE医疗的AI辅助心血管超声系统获得FDA批准，旨在缩短检查时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d812029338b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准吉利德的Trodelvy治疗三阴性乳腺癌

2021-11-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2020-09-14

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤

2020-08-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准非小细胞肺癌的辅助疗法，疾病复发率降低80％

2021-02-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤

2021-06-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2021年上半年盘点：FDA批准52款新药，6款生物制品

2021-11-08

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准新的医疗器械漏洞评分工具CVSS

2021-07-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

罗氏诊断HIV-1/HIV-2定性检测试剂获FDA批准

2020-11-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌

2021-03-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

异源细胞疗法FCR001治疗重度硬皮病：IND已获FDA批准

2020-08-20

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿

2021-07-31

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准遗传性肥胖药物Imcivree

2021-10-31

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准转基因猪，推进医疗用途的异种移植

2021-03-28

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准替格瑞洛用于降低卒中风险

2021-08-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准第三款新冠疫苗紧急使用授权

2021-12-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验

2021-03-20

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物

2021-03-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

艾滋病治疗革命：FDA批准长效HIV药物，每月仅需一次治疗

2021-10-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

PD-1单抗KEYTRUDA：首次获FDA批准治疗复发或转移性皮肤鳞状细胞癌

2021-02-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

GE医疗的AI辅助心血管超声系统获得FDA批准，旨在缩短检查时间

2021-04-14

科室
- - 订阅+
  - 更多科室
工具
服务